Pasar al contenido principal

LA CONEXION ENTRE EL LRP1 CARDIACO Y LOS NIVELES CIRCULANTES DEL PEPTIDO NATRIURETICO ANP COMO FUENTE DE NUEVAS OPORTUNIDADES DIAGNOSTICAS Y TERAPEUTICAS EN DIABETES TIPO 2

PI18/01584

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, M.P.
Centro realización INSTITUTO DE INV. BIOMEDICAS BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunization with the Gly 1127 -Cys 1140 amino acid sequence of the LRP1 receptor reduces atherosclerosis in rabbits. Molecular, immunohistochemical and nuclear imaging studies

  • Bornachea, Olga
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Nasarre, Laura
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Cedó, Lídia|||0000-0003-4354-3411
  • Iborra Obiols, Antoni|||0000-0002-8984-5151
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Juárez Rubio, Cándido|||0000-0003-2235-9893
  • Cámara, Juan Antonio|||0000-0001-7494-1127
  • Espinet, Carina|||0000-0001-8580-6617
  • Borrell-Pages, Maria|||0000-0002-1759-9756
  • Badimon, Lina|||0000-0002-9162-2459
  • Castell-Conesa, Joan|||0000-0002-6449-9731
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Background : The LRP1 (CR9) domain and, in particular, the sequence Gly 1127 -Cys 1140 (P3) plays a critical role in the binding and internalization of aggregated LDL (agLDL). We aimed to evaluate whether immunization with P3 reduces high-fat diet (HFD)-induced atherosclerosis. Methods : Female New Zealand White (NZW) rabbits were immunized with a primary injection and four reminder doses (R1-R4) of IrP (irrelevant peptide) or P3 conjugated to the carrier. IrP and P3-immunized rabbits were randomly divided into a normal diet group and a HFD-fed group. Anti-P3 antibody levels were determined by ELISA. Lipoprotein profile, circulating and tissue lipids, and vascular pro-inflammatory mediators were determined using standardized methods while atherosclerosis was determined by confocal microscopy studies and non-invasive imaging (PET/CT and Doppler ultrasonography). Studies treating human macrophages (hMΦ) and coronary vascular smooth muscle cells (hcVSMC) with rabbit serums were performed to ascertain the potential impact of anti-P3 Abs on the functionality of these crucial cells. Results : P3 immunization specifically induced the production of anti-P3 antibodies (Abs) and did not alter the lipoprotein profile. HFD strongly induced cholesteryl ester (CE) accumulation in the aorta of both the control and IrP groups, and their serum dose-dependently raised the intracellular CE of hMΦ and hcVSMC, promoting TNFR1 and phospho-NF-kB (p65) overexpression. These HFD pro-inflammatory effects were dramatically decreased in the aorta of P3-immunized rabbits and in hMΦ and hcVSMC exposed to the P3 rabbit serums. Microscopy studies revealed that P3 immunization reduced the percentage of lipids, macrophages, and SMCs in the arterial intima, as well as the atherosclerotic extent and lesion area in the aorta. PET/CT and Doppler ultrasonography studies showed that the average standardized uptake value (SUV) of the aorta and the arterial resistance index (ARI) of the carotids were more upregulated by HFD in the control and IrP groups than the P3 group. Conclusions : P3 immunization counteracts HFD-induced fatty streak formation in rabbits. The specific blockade of the LRP1 (CR9) domain with Anti-P3 Abs dramatically reduces HFD-induced intracellular CE loading and harmful coupling to pro-inflammatory signaling in the vasculature.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biophysical and Lipidomic Biomarkers of Cardiac Remodeling Post-Myocardial Infarction in Humans

  • Martinez de Lejarza Samper, Ignacio Miguel|||0000-0003-0337-3446
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Viladés Medel, David|||0000-0002-3638-9703
  • Dandurand, Jany
  • Casas, Josefina|||0000-0002-7926-5209
  • Jorge, Esther|||0000-0002-2777-0000
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Carreras Costa, Francesc|||0000-0002-1944-0562
  • Leta, Rubén|||0000-0003-4691-381X
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Few studies have analyzed the potential of biophysical parameters as markers of cardiac remodeling post-myocardial infarction (MI), particularly in human hearts. Fourier transform infrared spectroscopy (FTIR) illustrates the overall changes in proteins, nucleic acids and lipids in a single signature. The aim of this work was to define the FTIR and lipidomic pattern for human left ventricular remodeling post-MI. A total of nine explanted hearts from ischemic cardiomyopathy patients were collected. Samples from the right ventricle (RV), left ventricle (LV) and infarcted left ventricle (LV INF) were subjected to biophysical (FTIR and differential scanning calorimetry, DSC) and lipidomic (liquid chromatography-high-resolution mass spectrometry, LC-HRMS) studies. FTIR evidenced deep alterations in the myofibers, extracellular matrix proteins, and the hydric response of the LV INF compared to the RV or LV from the same subject. The lipid and esterified lipid FTIR bands were enhanced in LV INF, and both lipid indicators were tightly and positively correlated with remodeling markers such as collagen, lactate, polysaccharides, and glycogen in these samples. Lipidomic analysis revealed an increase in several species of sphingomyelin (SM), hexosylceramide (HexCer), and cholesteryl esters combined with a decrease in glycerophospholipids in the infarcted tissue. Our results validate FTIR indicators and several species of lipids as useful markers of left ventricular remodeling post-MI in humans.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma microRNA Profiling Reveals Novel Biomarkers of Epicardial Adipose Tissue, A Multidetector Computed Tomography Study

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Viladés Medel, David|||0000-0002-3638-9703
  • Martínez-Camblor, Pablo|||0000-0001-7845-3905
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Ferrero-Gregori, Andreu|||0000-0001-6492-2416
  • Nasarre, Laura
  • Bornachea, Olga
  • Sánchez Vega, Jesús|||0000-0001-7250-8362
  • Leta, Rubén|||0000-0003-4691-381X
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Benitez, Sonia|||0000-0003-3565-0743
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Carreras Costa, Francesc|||0000-0002-1944-0562
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Epicardial adipose tissue (EAT) constitutes a novel parameter for cardiometabolic risk assessment and a target for therapy. Here, we evaluated for the first time the plasma microRNA (miRNA) profile as a source of biomarkers for epicardial fat volume (EFV). miRNAs were profiled in plasma samples from 180 patients whose EFV was quantified using multidetector computed tomography. In the screening study, 54 deregulated miRNAs were identified in patients with high EFV levels (highest tertile) compared with matched patients with low EFV levels (lowest tertile). After filtering, 12 miRNAs were selected for subsequent validation. In the validation study, miR-15b-3p, miR-22-3p, miR-148a-3p miR-148b-3p and miR-590-5p were directly associated with EFV, even after adjustment for confounding factors (p value < 0.05 for all models). The addition of miRNA combinations to a model based on clinical variables improved the discrimination (area under the receiver-operating-characteristic curve (AUC) from 0.721 to 0.787). miRNAs correctly reclassified a significant proportion of patients with an integrated discrimination improvement (IDI) index of 0.101 and a net reclassification improvement (NRI) index of 0.650. Decision tree models used miRNA combinations to improve their classification accuracy. These results were reproduced using two proposed clinical cutoffs for epicardial fat burden. Internal validation corroborated the robustness of the models. In conclusion, plasma miRNAs constitute novel biomarkers of epicardial fat burden.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Low-density lipoprotein receptor-related protein 1 deficiency in cardiomyocytes reduces susceptibility to insulin resistance and obesity

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Bornachea, Olga
  • Cedó, Lídia|||0000-0003-4354-3411
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Herrero, Laura|||0000-0003-4244-4673
  • Roglans, Nuria
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Nasarre, Laura
  • Camino-López, Sandra|||0000-0002-2737-4892
  • García, Eduardo
  • Mato, Eugènia|||0000-0001-8121-9335
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sebastian, David
  • Laguna, Joan Carles|||0000-0002-2357-1186
  • Serra, Dolors|||0000-0002-4936-4206
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Background: Low-density lipoprotein receptor-related protein 1 (LRP1) plays a key role in fatty acid metabolism and glucose homeostasis. In the context of dyslipemia, LRP1 is upregulated in the heart. Our aim was to evaluate the impact of cardiomyocyte LRP1 deficiency on high fat diet (HFD)-induced cardiac and metabolic alterations, and to explore the potential mechanisms involved. Methods: We used TnT-iCre transgenic mice with thoroughly tested suitability to delete genes exclusively in cardiomyocytes to generate an experimental mouse model with conditional Lrp1 deficiency in cardiomyocytes (TNT-iCre+-LRP1flox/flox). Findings: Mice with Lrp1-deficient cardiomyocytes (cm-Lrp1-/-) have a normal cardiac function combined with a favorable metabolic phenotype against HFD-induced glucose intolerance and obesity. Glucose intolerance protection was linked to higher hepatic fatty acid oxidation (FAO), lower liver steatosis and increased whole-body energy expenditure. Proteomic studies of the heart revealed decreased levels of cardiac pro-atrial natriuretic peptide (pro-ANP), which was parallel to higher ANP circulating levels. cm-Lrp1-/- mice showed ANP signalingactivation that was linked to increased fatty acid (FA) uptake and increased AMPK/ ACC phosphorylation in the liver. Natriuretic peptide receptor A (NPR-A) antagonist completely abolished ANP signaling and metabolic protection in cm-Lrp1-/- mice. Conclusions: These results indicate that an ANP-dependent axis controlled by cardiac LRP1 levels modulates AMPK activity in the liver, energy homeostasis and whole-body metabolism.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting cholesteryl ester accumulation in the heart improves cardiac insulin response

  • Actis Dato, Virginia|||0000-0002-9071-8045
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Claudi, Lene
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Iborra Obiols, Antoni|||0000-0002-8984-5151
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Samouillan, Valerie|||0000-0003-0571-3985
  • Enrich, Carlos|||0000-0003-0382-2993
  • Chiabrando, Gustavo Alberto
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Background: Antibodies against the P3 sequence (Gly1127-Cys1140) of LRP1 (anti-P3 Abs) specifically block cholesteryl ester (CE) accumulation in vascular cells. LRP1 is a key regulator of insulin receptor (InsR) trafficking in different cell types. The link between CE accumulation and the insulin response are largely unknown. Here, the effects of P3 peptide immunization on the alterations induced by a high-fat diet (HFD) in cardiac insulin response were evaluated. Methods: Irrelevant (IrP)- or P3 peptide-immunized rabbits were randomized into groups fed either HFD or normal chow. Cardiac lipid content was characterized by thin-layer chromatography, confocal microscopy, and electron microscopy. LRP1, InsR and glucose transporter type 4 (GLUT4) levels were determined in membranes and total lysates from rabbit heart. The interaction between InsR and LRP1 was analyzed by immunoprecipitation and confocal microscopy. Insulin signaling activity and glucose uptake were evaluated in HL-1 cells exposed to rabbit serum from the different groups. Findings: HFD reduces cardiac InsR and GLUT4 membrane levels and the interactions between LRP1/InsR. Targeting the P3 sequence on LRP1 through anti-P3 Abs specifically reduces CE accumulation in the heart independently of changes in the circulating lipid profile. This restores InsR and GLUT4 levels in cardiac membranes as well as the LRP1/InsR interactions of HFD-fed rabbits. In addition, anti-P3 Abs restores the insulin signaling cascade and glucose uptake in HL-1 cells exposed to hypercholesterolemic rabbit serum. Interpretation: LRP1-immunotargeting can block CE accumulation within the heart with specificity, selectivity, and efficacy, thereby improving the cardiac insulin response; this has important therapeutic implications for a wide range of cardiac diseases. Funding: Fundació MARATÓ TV3: grant 101521-10, Instiuto de Salud Carlos III (ISCIII) and ERDF PI18/01584, Fundación BBVA Ayudas a Equipos de Investigación 2019. SECyT-UNC grants PROYECTOS CONSOLIDAR 2018-2021; FONCyT, Préstamo BID PICT grant 2015-0807 and grant 2017-4497.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development of Innovative Antiatherosclerotic Peptides through the Combination of Molecular Modeling and a Dual (Biochemical-Cellular) Screening System

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Pallara, C.
  • Nasarre, Laura
  • Ferreira, R.
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Prades, Roger
  • Tarragó, T.
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Cardiovascular disease (CVD) is a leading cause of death worldwide. Approximately 60% of patients treated with low-density lipoprotein (LDL)-lowering drug treatments, with on-target plasma cholesterol levels, are still suffering clinical acute ischemic events. Mechanisms, such as LDL aggregation, underlie extracellular and intracellular cholesterol accumulation in the vasculature. A peptide sequence (P3) of the low-density lipoprotein receptor-related protein 1 (LRP1) efficiently protects LDL from sphingomyelinase (SMase-) and phospholipase A2 (PLA)-induced LDL aggregation. The aim is to design families of peptide derivatives from P3 with enhanced potency and proteolytic stability. New peptides are designed through in silico conformational sampling and ApoB-100 molecular docking, and are tested in dual (biochemical-cellular) screening assays. A total of 46 new peptides including linear, fragment, cyclic, and alanine scanning derivatives are generated through two consecutive optimization rounds. Structurally and functionally optimized peptides contain hotspot residues that are replaced by alanine. This strategy confers an increased capacity to form prone alpha-helix conformations crucial for the electrostatic interaction with ApoB-100. These new compounds are highly efficient at inhibiting LDL aggregation and human coronary vascular smooth muscle cell-cholesteryl ester loading and should be studied in preclinical models of atherosclerosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD

  • Weber, Minéia
  • Mera, Paula|||0000-0001-8941-4637
  • Casas, Josefina|||0000-0002-7926-5209
  • Salvador, Javier
  • Rodríguez, Amaia|||0000-0002-2180-461X
  • Alonso Muñoz, Sergio|||0000-0002-3989-8757
  • Sebastián, David|||0000-0002-7260-3869
  • Soler Vázquez, M. Carmen|||0000-0003-1430-5617
  • Montironi, Carla|||0000-0002-1453-2193
  • Recalde, Sandra|||0000-0002-6174-0649
  • Fucho, Raquel|||0000-0002-1774-9099
  • Calderon-Dominguez, María|||0000-0003-1797-3450
  • Mir, Joan Francesc|||0000-0001-8501-0969
  • Bartrons, Ramon|||0000-0001-9349-5847
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Sánchez-Infantes, David|||0000-0001-6086-7501
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Casals, Nuria|||0000-0002-6719-4300
  • Valentí, Victor|||0000-0002-7074-2849
  • Frühbeck, Gema|||0000-0002-8305-7154
  • Herrero, Laura|||0000-0003-4244-4673
  • Serra, Dolors|||0000-0002-4936-4206
The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased drastically due to the global obesity pandemic but at present there are no approved therapies. Here, we aimed to revert high-fat diet (HFD)-induced obesity and NAFLD in mice by enhancing liver fatty acid oxidation (FAO). Moreover, we searched for potential new lipid biomarkers for monitoring liver steatosis in humans. We used adeno-associated virus (AAV) to deliver a permanently active mutant form of human carnitine palmitoyltransferase 1A (hCPT1AM), the key enzyme in FAO, in the liver of a mouse model of HFD-induced obesity and NAFLD. Expression of hCPT1AM enhanced hepatic FAO and autophagy, reduced liver steatosis, and improved glucose homeostasis. Lipidomic analysis in mice and humans before and after therapeutic interventions, such as hepatic AAV9-hCPT1AM administration and RYGB surgery, respectively, led to the identification of specific triacylglyceride (TAG) specie (C50:1) as a potential biomarker to monitor NAFFLD disease. To sum up, here we show for the first time that liver hCPT1AM gene therapy in a mouse model of established obesity, diabetes, and NAFLD can reduce HFD-induced derangements. Moreover, our study highlights TAG (C50:1) as a potential noninvasive biomarker that might be useful to monitor NAFLD in mice and humans.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased sLRP1 and decreased atrial natriuretic peptide plasma levels in newly diagnosed T2DM patients are normalized after optimization of glycemic control

  • García, Eduardo
  • Gil, Pedro|||0000-0003-3707-7450
  • Miñambres, Inka|||0000-0002-0899-3938
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Rodríguez, Claudia
  • Claudi, Lene
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Benitez, Sonia|||0000-0003-3565-0743
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Garcia-Moll, Xavier|||0000-0001-7837-8378
  • Viladés Medel, David|||0000-0002-3638-9703
  • Pérez, Antonio|||0000-0001-5528-1143
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Low-density lipoprotein receptor-related protein 1 (LRP1) negatively modulates circulating atrial natriuretic peptide (ANP) levels. Both molecules are involved in the regulation of cardiometabolism. To evaluate soluble LRP1 (sLRP1) and ANP levels in people with newly diagnosed type 2 diabetes mellitus (T2DM) and determine the effects of metabolic optimization. This single-center longitudinal observational study recruited patients with newly diagnosed T2DM (n = 29, HbA1c.